Stock Market Reviews

Read and share opinions on PFE (Pfizer Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Pfizer (PFE) Braces for Bumpy Years as Growth Pushed Out to 2029
  Dec 30, 2025
• Here’s What Analysts Think About Pfizer Inc. (PFE)
  Dec 30, 2025
• Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
  Dec 26, 2025
• BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera
  Dec 25, 2025

PFE News

• Here’s What Analysts Think About Pfizer Inc. (PFE)
  Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price target of $30.00. The same day, Bernstein analyst Courtney Breen reiterated a Hold rating on the stock, keeping the associated price target the […]
  Dec 30, 2025
• Jim Cramer Names His Favorite Dividend Stocks
  Jim Cramer has built a strong reputation in the industry. He’s the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs. When it comes to dividend stocks, he thinks there are many stocks with a high yield, but as yields soar, it can become dangerous since ... Jim Cramer Names His Favorite Dividend Stocks
  Dec 29, 2025
• The Smartest Dividend Stocks to Buy With $3,000 Right Now
  These income stocks look like smart buys right now.
  Dec 29, 2025
• 3 Drug Stocks to Buy at a Discount
  The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
  Dec 27, 2025
• 3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now
  High dividend yields don't matter if they aren't supported by quality businesses.
  Dec 27, 2025
• This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
  Bristol Myers Squibb could become the pharmaceutical industry’s turnaround story for 2026. Shares are off 9% in 2025 after a series of drug pipeline disappointments, while major patent expirations, like one for cancer drug Revlimid, could cause earnings to fall 5% in 2026 and another 5% in 2027. At the current price, investors are paying little for Bristol Myers’ pipeline, led by Cobenfy, a schizophrenia drug being tested as a treatment for psychosis among Alzheimer’s patients, and Milvexian, a treatment of atrial fibrillation and strokes.
  Dec 27, 2025
• Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
  JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
  Dec 26, 2025
• Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
  Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Dec 26, 2025
• Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
  CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
  Dec 26, 2025
• This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%
  Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.
  Dec 26, 2025
• BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera
  Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than […]
  Dec 25, 2025
• As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?
  As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?
  Dec 25, 2025
• Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer's (PFE) Risk–Reward Story?
  Earlier in December 2025, Pfizer disclosed that a participant in its long-term Hympavzi hemophilia trial died following serious cerebrovascular complications, while also tightening revenue guidance for 2025 and issuing an initial outlook for 2026 that reflects ongoing patent and pricing headwinds. At the same time, Pfizer is leaning heavily on its oncology and immunology pipeline, including positive Phase 3 data for TUKYSA and PADCEV combinations and new AI-enabled and TCR-focused...
  Dec 24, 2025
• PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
  Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.
  Dec 24, 2025
• Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
  If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.
  Dec 24, 2025
• Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025
  Continued revenue growth and commercial projects fuel Telescope's successful intelligent automation and advanced chemical manufacturing portfolioVancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The...
  Dec 24, 2025
• Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
  In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.
  Dec 23, 2025
• Pfizer Stock Is Down -- Patient Death in Hemophilia Study Raises Safety Concerns
  Hemophilia Drug Hympavzi Under Scrutiny as Adverse Event Sparks Market Jitters
  Dec 23, 2025
• Sector Update: Health Care Stocks Mixed Late Afternoon
  Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally h
  Dec 23, 2025
• Will the Recent Pricing Deal With the Government Impact BMY's Sales?
  BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
  Dec 23, 2025
• Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
  XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.
  Dec 22, 2025
• Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503)
  In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event-free and overall survival, with higher pathologic complete response rates and a safety profile consistent with prior data. The strength of these pivotal results could meaningfully reinforce PADCEV’s role within Astellas’ oncology portfolio, particularly in earlier-stage bladder cancer where...
  Dec 22, 2025
• Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results
  Astellas Pharma (TSE:4503) just cleared an important milestone with Pfizer, as their PADCEV plus Keytruda combo hit primary and key secondary endpoints in a Phase 3 bladder cancer trial, sharpening the stock's long term growth story. See our latest analysis for Astellas Pharma. The market has been warming to that oncology story, with Astellas Pharma’s share price delivering a strong year to date return of 37.52 percent and a 1 year total shareholder return of 42.97 percent, underpinned by a...
  Dec 22, 2025
• Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
  Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.
  Dec 22, 2025
• Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer
  Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.
  Dec 22, 2025
• This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
  Vaxcyte stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note. Vaxcyte is advancing to phase 3 trials for its shot, VAX-31, in adults and phase 2 trials for infants. It could eventually be a leader in an $8 billion market, Mizuho argued.
  Dec 22, 2025
• Jim Cramer on Pfizer: “I’m Going to Say Just Weak Hold”
  Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer shed light on. During the lightning round, a caller sought Cramer’s opinion on the stock, and he said: “Okay, Pfizer, really good yield, not a lot of momentum. Didn’t like the update yesterday. I’m going to say just weak hold.” Pfizer Inc. (NYSE:PFE) creates and […]
  Dec 21, 2025
• Is Pfizer A Recovery Opportunity After Covid Vaccine Boom Fades?
  If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite a tough few years, the stock has inched up about 2.5% over the last year, even though it is still down roughly 5.3% year to date and more than 40% over three years, a mix that often signals shifting expectations around risk and recovery potential. Recent attention has focused on how Pfizer is...
  Dec 20, 2025
• MarketBeat Week in Review – 12/15 - 12/19
  Money continues to move into the market, raising hopes for a Santa Claus rally; however, the macro story remains mixed, which could bring more volatility
  Dec 20, 2025
• 1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm
  While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
  Dec 19, 2025
• Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
  We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]
  Dec 19, 2025
• Pharma's $370B Bet on America: The ETF Plays for 2026
  Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
  Dec 19, 2025
• Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
  Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
  Dec 19, 2025
• Better Buy in 2026: Pfizer or Merck?
  This year has been one to forget for these pharmaceutical giants.
  Dec 19, 2025
• Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer
  We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The […]
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact
  Today, the New York State Emerging Technology Advisory Board (ETAB) released its final report of recommendations to Governor Kathy Hochul. Led by co-chairs Deborah W. Brooks, CEO and co-founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF), and Andrew Baum, chief strategy and innovation officer of Pfizer, the ETAB's recommendations aim to bolster New York's position as a global biotechnology hub and as a place where innovation fuels healthier, stronger communities.
  Dec 19, 2025
• Down 80%, Should You Buy the Dip on Moderna?
  Your decision on whether to invest now depends to some extent on your investment strategy.
  Dec 19, 2025
• Novo files for CagriSema approval; Merck and Pfizer’s trial win
  Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.
  Dec 19, 2025
• 3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now
  The stocks listed here trade at forward earnings multiples of less than 18.
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap.
  The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.
  Dec 19, 2025
• White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay
  The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.
  Dec 19, 2025
• 3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
  J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
  Dec 18, 2025
• Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
  NEW YORK, December 18, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning.
  Dec 18, 2025
• Better Buy in 2026: Pfizer or Eli Lilly?
  These two stocks have been going in opposite directions over the past few years.
  Dec 18, 2025
• CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
  CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
  Dec 17, 2025
• Company News for Dec 17, 2025
  Companies in The News Are: PFE,KHC,F,PYPL
  Dec 17, 2025
• Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Pfizer Inc tops our list for being one of the most undervalued pharmaceutical stocks. On Friday, December 12, 2025, The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE., while lowering the price target to $28 from […]
  Dec 17, 2025
• Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
  PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
  Dec 17, 2025
• Stocks Gain Pre-Bell as Traders Parse Latest Employment Data
  The main US stock measures were tracking in the green in Wednesday's premarket activity as traders d
  Dec 17, 2025
• Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
  COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm
  Dec 17, 2025
• PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
  Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) vers
  Dec 17, 2025
• If I Could Only Buy and Hold a Single Stock, This Would Be It
  Pfizer's shares look attractive to investors willing to show patience.
  Dec 17, 2025
• The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now
  It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.
  Dec 17, 2025
• Dow, S&P 500 Fall For Third Straight Day Following Jobs Report
  The Dow Jones Industrial Average and the S&P 500 fell for a third straight session on Tuesday as tra
  Dec 16, 2025
• Why Pfizer (PFE) Stock Is Sliding Today
  Pfizer Sees Revenue Decline, Shifts Focus to New Drugs
  Dec 16, 2025
• UK Gaming Tax Hike And New Director Appointment Might Change The Case For Investing In Flutter Entertainment (FLUT)
  In December 2025, Flutter Entertainment PLC announced that Sally Susman, Pfizer’s Executive Vice President and Chief Corporate Affairs Officer, would join its Board as a non-executive director following the company’s Annual General Meeting on May 29, 2026, bringing extensive global communications and corporate affairs experience from roles at Pfizer, Estée Lauder, and American Express. This appointment comes shortly after the UK Budget introduced sharp increases in online gaming and sports...
  Dec 16, 2025
• Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline
  Loss of exclusivity and lower pandemic-related demand weigh on outlook.
  Dec 16, 2025
• Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
  NEW YORK, December 16, 2025--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors.
  Dec 16, 2025
• Tepid 2026 outlook dents Pfizer shares
  Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues while limiting shareholder payouts.The drugmaker expects a drop of $1.5 billion in 2026 revenues tied to lower Covid-19 sales and the decline of another $1.5 billion from products experiencing a loss of exclusivity.
  Dec 16, 2025
• Top Midday Stories: Pfizer Falls Following 2026 Outlook; Netflix-iHeartMedia Exclusive Deal; Apple's Possible iPhone Lineup Expansion
  All three major US stock indexes were pointing lower in late-morning trading on Tuesday, as investor
  Dec 16, 2025
• Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
  In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day.
  Dec 16, 2025
• Sector Update: Health Care Stocks Retreat Late Afternoon
  Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and
  Dec 16, 2025
• Equities Fall Intraday as Markets Evaluate Macro Data
  US benchmark equity indexes were lower intraday as traders parsed the latest economic data, includin
  Dec 16, 2025
• Pfizer outlook, Humana leadership shake-up, Kraft Heinz's new CEO
  Pfizer (PFE), Humana (HUM), and Kraft Heinz (KHC) are some of the trending tickers on Yahoo Finance's platform on Tuesday. Market Domination host Josh Lipton and Yahoo Finance Senior Reporter Brooke DiPalma examine the stories driving investor interest in the names. To watch more expert insights and analysis on the latest market action, check out more Market Domination.
  Dec 16, 2025
• Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue
  Pfizer (PFE) just laid out a 2026 outlook that underwhelmed the market, with lower expected earnings and revenue as COVID-19 sales fade and key drugs lose exclusivity, putting near term growth firmly under the microscope. See our latest analysis for Pfizer. Even with today’s dip on the 2026 guidance, Pfizer’s 90 day share price return of 10.59% suggests sentiment has been quietly improving, while the 1 year total shareholder return of 12.25% hints that long term confidence is slowly...
  Dec 16, 2025
• 1 Bold Prediction for Viking Therapeutics in 2026
  Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.
  Dec 16, 2025
• Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures
  Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the lucrative obesity market.
  Dec 16, 2025
• Stock Market Today: Dow Slides, Nasdaq Positive After Jobs Data; Nvidia Rises (Live Coverage)
  Stock Market Today: The Dow Jones index dropped Tuesday after a surprise November jobs report. Palantir and Tesla traded lower.
  Dec 16, 2025
• Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High
  Monte Rosa Therapeutics surged Tuesday after the biotech said an entire group in a prostate cancer study responded to its treatment.
  Dec 16, 2025
• These Stocks Moved the Most Today: Tesla, Pfizer, Humana, Circle, CoreWeave, Broadcom, IonQ, Ford, Navan, and More
  Stocks were mixed Tuesday as U.S. hiring in November was stronger than expected and the unemployment rate jumped to 4.6%. Ford was up 0.2%. The auto maker announced a pivot toward hybrids and away from electric cars.
  Dec 16, 2025
• Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise'
  Pfizer stock tumbled Tuesday after the drugmaker missed Wall Street's earnings forecast following a suite of acquisitions.
  Dec 16, 2025
• Pfizer CEO Defends Vaccines, Promises Growth by End of Decade
  Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as I said, this is an anomaly that will correct itself, I hope pretty soon,” Bourla said. Pfizer shares were down 4.9% Tuesday to $25.13 after the company issued 2026 guidance that came in slightly below expectations and said it expects a return to growth at the end of the decade.
  Dec 16, 2025
• Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast
  Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.
  Dec 16, 2025
• BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
  BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
  Dec 15, 2025
• Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial
  IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical development. This milestone underscores IDEAYA’s push to convert promising early uveal melanoma data and multiple FDA designations for darovasertib into a potential accelerated...
  Dec 15, 2025
• Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
  Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Dec 15, 2025
• GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
  DSMB Ends Comparator Arm; Trial Proceeds Exclusively With GEO-CM04S1 Following mRNA Vaccine's Failure to Meet Primary Endpoint Phase 2 Data Reinforce GEO-CM04S1 as an Important Next-generation Vaccine Candidate for the 40 Million U.S. and 400 Million...
  Dec 15, 2025
• Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
  A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat
  Dec 15, 2025
• Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
  Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
  Dec 14, 2025
• Forget Teladoc and Buy This Healthcare Stock Instead
  It's time for investors to give up on the telemedicine leader.
  Dec 13, 2025
• Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
  LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
  Dec 12, 2025
• Pfizer Declares First-Quarter 2026 Dividend
  NEW YORK, December 12, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer.
  Dec 12, 2025
• Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.
  Keep your expectations in check.
  Dec 12, 2025
• The Best Turnaround Stock to Invest $1,000 in Right Now
  Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.
  Dec 12, 2025
• CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
  CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
  Dec 11, 2025
• GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
  GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
  Dec 11, 2025
• Pfizer plans job cuts in Switzerland to reduce expenses
  The cuts follow a broader downgrading of the drug manufacturer’s Swiss operations.
  Dec 11, 2025
• Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
  Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.
  Dec 11, 2025
• Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study
  Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients […]
  Dec 11, 2025
• Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
  ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
  Dec 11, 2025
• IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
  IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free
  Dec 11, 2025
• How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating
  Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer expectations for revenue growth are set against a more supportive backdrop for U.S. drug pricing and renewed interest in large cap biopharma, helping to stabilize the valuation case. As these shifts play out alongside evolving views on Pfizer’s pipeline and deal making, investors can follow the...
  Dec 11, 2025
• Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience
  Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.
  Dec 11, 2025
• PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
  Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
  Dec 10, 2025
• JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
  JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
  Dec 10, 2025
• Sector Update: Health Care Stocks Climb Late Afternoon
  Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index adding 1.6% and the
  Dec 10, 2025
• China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer
  US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050
  Dec 10, 2025
• Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI
  Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison […]
  Dec 10, 2025
• Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
  The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
  Dec 10, 2025
• TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
  NEW YORK, December 10, 2025--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amo
  Dec 10, 2025
• The Fed’s Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today.
  What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to start your day.
  Dec 10, 2025
• This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)
  Invesco High Dividend Low Volatility ETF (NYSEARCA:SPHD) generates its 4.71% yield – roughly three times the S&P 500’s current dividend – by holding a concentrated portfolio of 50 U.S. stocks selected for high dividend yields and low volatility. With $3.1 billion in assets and a reasonable 0.30% expense ratio, SPHD takes an equal-weight approach to ... This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500)
  Dec 10, 2025
• What Pfizer (PFE)'s GLP-1 Obesity Deal and Hemophilia Data Mean For Shareholders
  Recently, Pfizer Inc. announced an exclusive global collaboration and license agreement with YaoPharma to develop, manufacture and commercialize YP05002, an oral small-molecule GLP-1 receptor agonist currently in Phase 1 for chronic weight management, alongside new Phase 3 data showing HYMPAVZI improved bleeding outcomes for people with hemophilia A or B with inhibitors. The YaoPharma deal, which includes a US$150 million upfront payment and potential milestones of up to US$1.94 billion plus...
  Dec 9, 2025
• Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
  Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
  Dec 9, 2025
• Top Midday Stories: Nvidia H200 AI Chips' China Access; Google's EU Antitrust Probe; Amazon New York Drivers Join Teamsters Union
  All three major US stock indexes were edging higher in late-morning trading on Tuesday after the Fed
  Dec 9, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.6% and th
  Dec 9, 2025
• Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill
  Agreement deepens company's push into fast-growing weight-loss market
  Dec 9, 2025
• Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
  Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece
  Dec 9, 2025
• Pfizer Strikes Licensing Deal For Chinese Company's Obesity Drug Candidate
  Pfizer (PFE) said Tuesday that it will develop Chinese drug manufacturer YaoPharma's weight loss the
  Dec 9, 2025
• Down 50%, Should You Buy the Dip on Pfizer?
  Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.
  Dec 9, 2025
• Strategic Pharma Collaborations Propel RCC Market Growth
  The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi
  Dec 9, 2025
• Pfizer dips into China for another try at an obesity pill
  A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.
  Dec 9, 2025
• CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response
  By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful development and commercialization of onvansertib for first line treatment of patients with metastatic colorectal cancer (mCRC). Onvansertib is a Polo-Like kinase 1 (PLK1)
  Dec 9, 2025
• Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
  NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana
  Dec 9, 2025
• Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.
  Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.
  Dec 9, 2025
• In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?
  In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.
  Dec 9, 2025
• Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
  This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.
  Dec 9, 2025
• Drugmakers Are Ditching Middlemen to Sell Directly to Patients
  Companies are rolling out direct-to-patient services, which are selling drugs for weight loss and other uses.
  Dec 8, 2025
• Can Pfizer’s Recent Recovery Signal a Long Term Value Opportunity in 2025?
  Wondering if Pfizer is quietly turning into a value opportunity, or if the market is still too skeptical, you are not alone. That is exactly what this breakdown will unpack. After a rough few years, Pfizer's share price has ticked up 1.1% over the last week and 5.8% over the past month, even though it is still down 2.2% year to date and 40.1% over three years, with a modest 8.5% gain over the last year. Recent sentiment has been shaped by Pfizer's shifting pipeline strategy and portfolio...
  Dec 6, 2025
• HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
  NEW YORK, December 06, 2025--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no t
  Dec 6, 2025
• Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
  Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
  Dec 6, 2025
• 3 Reasons PFE is Risky and 1 Stock to Buy Instead
  Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.
  Dec 5, 2025
• Pfizer Inc. (PFE): A Bull Case Theory
  We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.27 as of December 1st. PFE’s trailing and forward P/E were 14.97 and 8.50 respectively according to Yahoo Finance. Pfizer Inc. (PFE) has emerged from the post-COVID period as a transformed […]
  Dec 5, 2025
• 3 Low-Volatility Stocks with Warning Signs
  Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
  Dec 5, 2025
• Why Is Moderna (MRNA) Stock Rocketing Higher Today
  Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.
  Dec 5, 2025
• Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
  CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
  Dec 5, 2025
• Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
  Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
  Dec 5, 2025
• Do These 3 Healthcare Stocks Need a Checkup?
  These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?
  Dec 5, 2025
• 2 Headwinds Facing Pfizer Stock Going Into 2026
  There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.
  Dec 5, 2025
• Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?
  Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 4, 2025
• Jim Cramer on Pfizer: “I Would Hold on to It”
  Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think […]
  Dec 4, 2025
• 3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
  In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
  Dec 4, 2025
• Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
  Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases. ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified
  Dec 4, 2025
• Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing
  The report highlights opportunities in pharmaceutical outsourcing through emerging trends, new contracts, M&A activities, and investments in technology. It guides CMOs, pharmaceutical decision-makers, and investors in strategic planning and supplier management by providing insights into regulatory impacts and supply chain developments.Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, October 2025" report has been added to ResearchAndMarkets.com's offering.The
  Dec 4, 2025
• Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight
  The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. In addition, the increasing prevalence and the launch of emerging therapies, such as inclacumab (Pfizer), etavopivat (Novo Nordisk), mitapivat (Agios Pharmaceuticals), osivelotor (Pfizer), and others, will also contribute to the growing market size during the forecast period.New York, USA, De
  Dec 3, 2025
• Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
  Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
  Dec 2, 2025
• If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now?
  Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, and healthcare products. It is set to report its Q4 2025 earnings on Feb. 3. Wall Street analysts expect the company ...
  Dec 2, 2025
• Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
  Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
  Dec 2, 2025
• LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
  Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
  Dec 2, 2025
• Vaccine stocks brace for shock waves at this week’s ACIP meeting
  Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.
  Dec 2, 2025
• Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
  Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
  Dec 2, 2025
• Assessing Pfizer's (PFE) Valuation After Recent Share Price Rebound
  Pfizer (PFE) shares have shown some movement this week, drawing attention for investors evaluating the company’s current position and recent performance. The stock’s slight rebound over the past month is notable, particularly after a period of declines earlier this year. See our latest analysis for Pfizer. Pfizer’s share price has turned a corner after earlier weakness this year, with a modest 2.5% gain over the past month that points to emerging momentum. However, the long-term picture...
  Dec 2, 2025
• Nanopharmaceuticals Research Report 2025: Market to Reach $104.58 Billion by 2030, Driven by Rising Chronic Disease Burden and Growing Investment in Regenerative Medicine and Nanotechnology Drugs
  The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor
  Dec 2, 2025
• 2 Top Dividend Stocks to Buy Now and Hold For a Decade
  These healthcare leaders can make you money while you sleep.
  Dec 2, 2025
• How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
  Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam Pharmaceuticals.
  Dec 2, 2025
• AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
  Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
  Dec 1, 2025
• VKTX Stock Rises 34% in Three Months: Here's What You Should Know
  Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
  Dec 1, 2025
• 1 Profitable Stock on Our Buy List and 2 We Turn Down
  While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
  Dec 1, 2025
• Vaccine makers fall on FDA memo, Bally's wins bid for NYC casino
  Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the stock hit vaccine makers Moderna (MRNA), BioNTech (BNTX), and Novavax (NVAX) are taking on following a memo from the US Food and Drug Administration (FDA); casino operator Bally's (BALY) has won approval to run casinos in New York City; and Somnigroup International's (SGI) $1.6 billion offer to acquire Leggett & Platt (LEG). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
  Dec 1, 2025
• Shares of vaccine makers drop after FDA memo flags reports of child deaths
  Investing.com -- Shares in major COVID-19 vaccine makers fell on Monday after an internal U.S. Food and Drug Administration (FDA) memo reportedly suggested that vaccinations may have contributed to several child deaths linked to heart inflammation.
  Dec 1, 2025
• Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
  NEW YORK, December 01, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer’s full-year 2026 financial guidance.
  Dec 1, 2025
• Will Korlym Continue to Drive Corcept's Top Line in 2026?
  CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
  Dec 1, 2025
• Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
  PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),
  Dec 1, 2025
• Stock market holiday shopping: How to find quality value names
  Retailers aren't the only ones with holiday sales; investors can also find high value for low prices in the stock market (^DJI, ^GSPC, ^IXIC). Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, explains where investors should look to find the best value stocks this holiday season. Catch more Stocks in Translation, with new episodes every Tuesday and Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
  Dec 1, 2025
• 2 Undervalued, High-Quality Companies to Buy Now and Hold Forever
  If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.
  Dec 1, 2025
• Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals
  The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
  Dec 1, 2025
• U.S., U.K. Strike Deal on Higher Drug Prices
  The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.
  Dec 1, 2025
• Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10
  Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.
  Dec 1, 2025
• Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals
  Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official claimed the shots led to 10 children’s deaths and said the agency would tighten vaccine-approval standards. Shares of Moderna and Novavax, which depend heavily on Covid-19 vaccine sales for revenue, fell about 6% and 3.5%, respectively. Stock in Pfizer, whose Covid-19 vaccine sales are a smaller percentage of total company revenue, ticked higher.
  Dec 1, 2025
• FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
  Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become stricter.
  Dec 1, 2025
• Will Michael Saylor’s Strategy Ever Join the S&P 500?
  Strategy has made no secret of the fact that it would like to join the S&P 500 — but at least for now, a spot in this flagship index remains elusive.Earlier this week, the Bitcoin treasury company was snubbed again, with Sandisk joining the ranks of America’s most prestigious large-cap ...
  Nov 30, 2025
• This 7% Yielder Could Be a Top AI Play
  One drug developer could be on the cusp of AI-powered glory.
  Nov 30, 2025
• 3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
  If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.
  Nov 30, 2025
• With 66% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns
  Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...
  Nov 29, 2025
• $92.91 Bn Nasal Drug Delivery Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030F
  The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The "Nasal Drug Delivery Market - Global Industry Size, Share,
  Nov 28, 2025
• Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating
  Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]
  Nov 28, 2025
• JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
  JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
  Nov 28, 2025
• Is Pfizer Stock Underperforming the Dow?
  While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.
  Nov 28, 2025
• Biotechs Are On A Big Run, And Two Stocks Have Buy Points
  Biotech stocks remain prevalent on the IBD 50 list of winning growth names. While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases. Biotech stocks have made tremendous progress off April lows.
  Nov 28, 2025
• Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
  NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
  Nov 27, 2025
• Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
  PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
  Nov 27, 2025
• Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
  These top dividend stocks could intrigue a wide range of investors.
  Nov 27, 2025
• AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
  ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
  Nov 26, 2025
• NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
  Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
  Nov 26, 2025
• Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
  Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease va
  Nov 26, 2025
• Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices
  The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,
  Nov 26, 2025
• Did Pfizer Just Say "Checkmate" to Novo Nordisk?
  The weight loss drug market may approach almost $100 billion by the end of the decade.
  Nov 26, 2025
• Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
  Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
  Nov 26, 2025
• Stocks to Watch Wednesday: Dell, HP, Workday, Li Auto
  ↗️ Dell (DELL): The computer and software maker raised full-year guidance and forecast AI server shipments would more than double. Shares rose nearly 5% premarket. ↘️ HP (HPQ): The computer and printer maker plans to cut up to 10% of its workforce as it invests further in artificial intelligence.
  Nov 26, 2025
• U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs
  The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs. The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes. The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.
  Nov 26, 2025
• J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?
  J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.
  Nov 25, 2025
• 4 takeaways from pharma’s manufacturing boom
  As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.
  Nov 25, 2025
• Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?
  Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...
  Nov 25, 2025
• Is This the Best Value Stock to Buy While Markets Are Volatile?
  This big pharma stock should be even more appealing to investors amid market turbulence.
  Nov 25, 2025
• Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial
  The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.
  Nov 25, 2025
• FDA Decision Opens Bigger Market for Novartis’s Blockbuster Gene Therapy
  Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.
  Nov 25, 2025
• Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment
  The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.
  Nov 25, 2025
• Moderna is the S&P 500's most shorted stock: Here's why
  President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.
  Nov 24, 2025
• Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
  LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
  Nov 24, 2025
• Mamdani Taps Ex-Goldman Partner, Developer for Transition Team
  Among those chosen to help in his move to City Hall are former Goldman Sachs Group Inc. partner Margaret Anadu, developer Jed Walentas and Kathy Wylde, head of the Partnership for New York City. Wylde and Anadu will serve on the Committee on Economic Development & Workforce Development, and Walentas will join the Committee on Housing, according to a statement from Mamdani’s transition team on Monday.
  Nov 24, 2025
• Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock
  A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.
  Nov 24, 2025
• FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
  Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
  Nov 24, 2025
• Urinary Tract Infection Treatment Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue
  The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads
  Nov 24, 2025
• Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
  Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.
  Nov 24, 2025
• Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
  NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b
  Nov 24, 2025
• RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum
  RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.
  Nov 24, 2025
• UnitedHealth Group Incorporated (UNH) Outlook Strong, Analysts Watch Closely
  UnitedHealth Group Incorporated (NYSE:UNH) is among the stocks Wall Street analysts are watching closely. On November 11, Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400. Earlier on November 3, a Barclays analyst had also maintained his Buy rating and a $386 price target. Analysts’ opinion on […]
  Nov 23, 2025
• Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025?
  Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped just 0.1% in the last week, inched up 1.3% over the past month, but are still down 5.9% year to date despite a 4.7% return over the last twelve months. Recent headlines about Pfizer have focused on its latest product developments and major moves in the pharmaceutical sector, generating speculation...
  Nov 22, 2025
• 2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon
  For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.
  Nov 22, 2025
• The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade
  Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...
  Nov 21, 2025
• U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
  NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy
  Nov 21, 2025
• PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
  Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
  Nov 21, 2025
• Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
  Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Nov 21, 2025
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health
  Nov 21, 2025
• Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.
  Nov 21, 2025
• FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
  RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a
  Nov 21, 2025
• This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase
  The drugmaker may not continue to lag the market for much longer.
  Nov 21, 2025
• Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.
  Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.
  Nov 21, 2025
• The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing
  Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing
  Nov 21, 2025
• Zoetis (ZTS): Buy, Sell, or Hold Post Q3 Earnings?
  Zoetis’s stock price has taken a beating over the past six months, shedding 28.6% of its value and falling to a new 52-week low of $116.88 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
  Nov 20, 2025
• BMO Launches New CDRs With Exposure to U.S. Stocks Including Apple, Intel, Mastercard, Pfizer and Visa
  Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.
  Nov 20, 2025
• Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
  BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
  Nov 20, 2025
• VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
  Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
  Nov 20, 2025
• Wall Street Gives Up on High-Yield Stocks
  When the AI bubble bursts, Altria will look like a pretty good investment again. It has paid out billions in dividends over the years, and that is unlikely to stop.
  Nov 20, 2025
• Is Pfizer's 6.9%-Yielding Dividend Still Safe?
  The company's earnings fell by 21% last quarter.
  Nov 20, 2025
• This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
  For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.
  Nov 20, 2025
• Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?
  Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?
  Nov 20, 2025
• White House Touts $270 Billion Worth of Deals at Saudi-palooza
  A day after the White House proclaimed that Saudi Arabia boosted its spring pledge to invest $600 billion in the US to a tidy $1 trillion during Crown Prince Mohammed bin Salman’s visit to Washington, DC, President Donald Trump said companies from both nations inked $270 billion in deals at a US-Saudi business forum. No timeline was given for Saudi Arabia’s $1 trillion in investments and, while the US-Saudi Investment Forum on Wednesday drew corporate royalty from Chevron, Tesla, Nvidia, Qualcomm, Cisco, General Dynamics, Pfizer and more, it wasn’t immediately clear which companies inked deals. Trump did say GE Aerospace will “deliver dozens of new engines” while a handful of other pacts, while short on financial details, highlighted some international bargaining.
  Nov 20, 2025
• Elon Musk, Jensen Huang to talk AI at US-Saudi investment forum
  WASHINGTON (Reuters) -Tesla CEO Elon Musk and Nvidia CEO Jensen Huang will take part in a discussion on ​advances in artificial intelligence and technology at a U.S.-Saudi ‌Arabia investment forum in Washington on Wednesday, according to a document seen by Reuters. "This conversation ‌will explore the emerging forces shaping the next wave of technological progress, highlighting the architectures, models, and investments powering a more intelligent and interconnected future," the document said. The event is planned for the day after Saudi Crown Prince ⁠Mohammed bin Salman, widely ‌known by his initials MBS, met with President Donald Trump at the White House.
  Nov 19, 2025
• Pfizer CEO on plans to bring down drug prices
  Pfizer (PFE) CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see lower drug prices. Pfizer is among the companies that have made deals with the White House on pharmaceutical pricing. Make sure to watch Yahoo Finance's full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.
  Nov 19, 2025
• PFE- The Winner in the Metsera Bidding War
  Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.
  Nov 19, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the
  Nov 19, 2025
• Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies
  Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati
  Nov 19, 2025
• Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck
  The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula
  Nov 19, 2025
• Bacterial Vaginosis Market Research Report 2025-2035, Competitive Analysis of Pfizer, Bayer, Exeltis USA, Lupin, Osel
  The global bacterial vaginosis market is experiencing rapid growth, fueled by a rise in incidence due to lifestyle and hygiene changes. Increasing awareness is driving demand for innovative treatments, including probiotics and precision medicine. Investments from both the government and private sector, especially in women's health, are accelerating market growth. However, challenges such as side effects of current treatments persist. As research advances and emphasis on sustainable solutions int
  Nov 19, 2025
• Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
  Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.
  Nov 19, 2025
• Business Leaders Set to Welcome Saudi Investments after a Combative White House Meeting
  Saudi Crown Prince Mohammed bin Salman’s overtures to U.S. political and business leaders will continue Wednesday, but on somewhat friendlier terms. Bin Salman, the de facto ruler of Saudi Arabia, took questions from the press alongside President Donald Trump Tuesday. The event turned combative after Trump bristled at a reporter’s probing questions.
  Nov 19, 2025
• A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%.
  Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a difference.
  Nov 19, 2025
• Why GRAIL Stock Could Be Biotech’s Next Big Breakout
  Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.
  Nov 19, 2025
• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
  Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.
  Nov 19, 2025
• J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
  J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
  Nov 18, 2025
• Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
  PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
  Nov 18, 2025
• Can AI Drive Peloton's Comeback?
  The market is hopping with interesting news.
  Nov 18, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal
  Nov 18, 2025
• Hemophilia B Research Report 2025-2035: Market Led by UniQure, Pfizer, Novo Nordisk, HEMA Biologics, and Alnylam Pharmaceuticals as Next-Generation Therapies and R&D Investment Drive Innovation
  The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqvez offer potential functional cures by reducing bleeding rates. Early detection using next-generation sequencing enhances patient management and personalized care. Despite challenges such as high costs and limited long-term safety data, leading companies like UniQure and Pfi
  Nov 18, 2025
• [Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
  [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.
  Nov 18, 2025
• Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma
  The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem
  Nov 18, 2025
• Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth
  Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are revolutionizing patient outcomes through less frequent dosing and potential long-term solutions. Rising awareness and improved diagnostics hasten early detection, boosting demand. However, high treatment costs and regulatory hurdles present challenges. Key players like Alnylam
  Nov 18, 2025
• Pfizer (PFE): Exploring Valuation After Recent Momentum in Share Price
  Pfizer (PFE) shares have shown resilience, with a modest uptick over the past week and month. Investors are keeping an eye on the stock’s performance as the company navigates market trends and changing sentiment. See our latest analysis for Pfizer. Despite a challenging year for many large-cap healthcare names, Pfizer's recent momentum hints at a shift in sentiment. While the share price is still down for the year to date, the one-year total shareholder return has turned positive. This...
  Nov 18, 2025
• Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE)
  As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
  Nov 18, 2025
• Pleural Effusion Market Research Report 2025-2035: Novatech, Sanofi, and Pfizer Lead Innovation Through Strategic Partnerships and R&D Expansion
  The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory health, and a rising demand for effective management solutions. Key drivers include the development of advanced drainage systems, anti-inflammatory drugs, and minimally invasive treatments like thoracentesis and pleurodesis. As awareness of pleural effusion's risks increases, early detection and intervention remain crucial. Despite ch
  Nov 18, 2025
• Hemophilia Research Analysis Report 2025-2035: Market Advances as Leading Players Accelerate Gene Therapy Innovation and Strategic Partnerships, Led by CSL Behring, Takeda, and Pfizer
  The global hemophilia market is experiencing robust growth, fueled by advances in gene therapy and recombinant clotting factors. Increased awareness and healthcare investment worldwide are expanding access to innovative treatments such as extended half-life therapies and novel biologics, enhancing patient outcomes. The U.S. market drives this expansion, supported by a strong healthcare infrastructure and evolving regulatory landscape. However, high therapy costs and regulatory hurdles remain cha
  Nov 18, 2025
• Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
  The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio
  Nov 18, 2025
• The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company
  Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.
  Nov 18, 2025
• Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It’s a Worry for the Stocks.
  Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
  Nov 18, 2025
• Nuvalent aiming for approval on pivotal trial data for NSCLC candidate
  Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting
  Nov 18, 2025
• MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
  Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
  Nov 17, 2025
• Down 55%, Should You Buy the Dip on Pfizer?
  Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.
  Nov 17, 2025
• PLX: Protalix Seeks Re-Examination of CHMP Opinion
  By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial
  Nov 17, 2025
• 2 Giant Healthcare Stocks to Buy Hand Over Fist in November
  Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.
  Nov 17, 2025
• Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment
  Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.
  Nov 17, 2025
• Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion
  Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”
  Nov 17, 2025
• A Look at BioNTech (NasdaqGS:BNTX) Valuation Following Pfizer’s Share Sale Announcement
  BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave of trading activity and market discussion. See our latest analysis for BioNTech. BioNTech’s share price has edged down nearly 2% this year, with momentum cooling further in recent months as investors weigh Pfizer’s exit and slowing Covid-19 vaccine revenues against a robust pivot back to oncology...
  Nov 15, 2025
• Is Pfizer Stock a Buy After This $10 Billion Acquisition?
  The company has been on an acquisition spree for years, and this one may be the most important yet.
  Nov 15, 2025
• Values that Pfizer and Delta CEOs draw on for great leadership
  At Yahoo Finance Invest 2025, Albert Bourla and Ed Bastian shared the values that helped them lead companies through crisis.
  Nov 15, 2025
• Novo Chairman Blames Board Dropout on Former Employer Pfizer
  The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.” “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said. Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.
  Nov 14, 2025
• Why Pfizer (PFE) Shares Are Sliding Today
  Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.
  Nov 14, 2025
• Merck agrees $9.2bn deal for flu-prevention biotech Cidara
  Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...
  Nov 14, 2025
• Pfizer Cuts BioNTech Stake by More Than Half
  Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.
  Nov 14, 2025
• How Recent Moves Are Rewriting the Story for Pfizer
  Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...
  Nov 14, 2025
• Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
  Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
  Nov 14, 2025
• Is that pharma influencer human or AI?
  Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.
  Nov 14, 2025
• Health Care Roundup: Market Talk
  Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.
  Nov 14, 2025
• Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
  Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.
  Nov 14, 2025
• To Wall Street, a new bidding war puts Alkermes in a tough spot
  Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.
  Nov 14, 2025
• Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since
  Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.
  Nov 14, 2025
• RFK Jr. would not have been my HHS pick: Pfizer CEO
  Health and Human Services Secretary Robert F. Kennedy, Jr. has come under fire for his views on vaccines. In an interview with Yahoo Finance, Pfizer (PFE) CEO Albert Bourla says that Kennedy wouldn't have been his pick to lead HHS. Find out why in the video above. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.
  Nov 13, 2025
• Sector Update: Health Care Stocks Edge Higher Late Afternoon
  Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index and the Health
  Nov 13, 2025
• Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
  Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Dire
  Nov 13, 2025
• Pfizer completes Metsera acquisition in deal worth up to $10 bn
  US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.
  Nov 13, 2025
• Pfizer CEO says RFK Jr. wasn't his 'first choice' for HHS Secretary
  Pfizer CEO Albert Bourla says RFK Jr.'s appointment was not up to him, but he has found common ground with the vaccine skeptic.
  Nov 13, 2025

PFE Reviews

• DividendDegen

  Dec 30, 2025

  $PFE Big plays in the health game, gotta keep an eye!

  Buy

• AlphaVandal

  Dec 29, 2025

  $PFE Pharma dreams turned into a nightmare; check your stocks.

  Sell

• ChartPhantom

  Dec 28, 2025

  $PFE They’re in the health game—keeping our bodies moving while making our wallets happy!

  Buy

• ManiaBroker

  Dec 28, 2025

  $PFE Developing medicines like it’s no big deal, but I still can’t find my phone half the time. Talk about priorities!

  Buy

• TradeReckoner

  Dec 27, 2025

  $PFE Pharma giant or just a big pharma headache?

  Sell

• CashCraze

  Dec 27, 2025

  $PFE This company stands at the forefront of pharmaceutical innovation, continually pushing the boundaries of research to develop groundbreaking treatments. Its commitment to addressing global health challenges positions it as a key player in the industry.

  Buy

• BearishBoi

  Dec 27, 2025

  $PFE This stock is like the science nerd who gets all the attention at prom—everyone wants to be seen with them, but remember, they also have a chemistry lab!

  Buy

• AlphaWave

  Dec 27, 2025

  $PFE This stock is an absolute rollercoaster! With constant scrutiny and market shifts, it's either a brilliant play or a gamble that could backfire. Tread carefully here!

  Sell

• TradeBlaze

  Dec 27, 2025

  $PFE A global leader in pharmaceuticals, this company continues to be at the forefront of medical advancements. Their extensive portfolio and ongoing commitment to innovation are crucial for addressing some of the world's most pressing health challenges.

  Buy

• MoonBagz

  Dec 26, 2025

  $PFE This pharma player's cookin' up the goods, watch it go!

  Buy

• PortfolioGremlin

  Dec 25, 2025

  $PFE Rolling with the big dogs in healthcare, they ain't slowing down!

  Buy

• DividendDemon

  Dec 25, 2025

  $PFE It's like that one friend who always has a plan—solid, reliable, and keeps the vibes good!

  Buy

• FiscalEngine

  Dec 23, 2025

  $PFE This pharmaceutical powerhouse continues to make headlines with its extensive pipeline and ongoing research efforts. Its significant role in healthcare and recent advancements suggest promising potential for future development.

  Buy

• CapitalNova

  Dec 23, 2025

  $PFE With a robust portfolio of healthcare products and a commitment to research and development, this organization continues to play a critical role in addressing global health challenges, showcasing resilience in uncertain times.

  Buy

• WallStreetRogue

  Dec 23, 2025

  $PFE In the ever-volatile world of pharmaceuticals, staying relevant is a daily struggle. With recent developments making headlines, will they rise to the occasion or falter under scrutiny? The stakes are high!

  Buy

• MarketMyth

  Dec 22, 2025

  $PFE This organization has a strong portfolio of products and a proven track record in the pharmaceutical industry. Ongoing research and development efforts position it well to address global health challenges effectively.

  Buy

• RocketDividend

  Dec 21, 2025

  $PFE Big player in the game, they keep droppin’ knowledge, respect!

  Buy

• BullishSniper

  Dec 21, 2025

  $PFE They’ve saved us from more colds than grandma’s chicken soup! Just make sure to give them a high-five next time you see them!

  Buy

• TradeTracer

  Dec 21, 2025

  $PFE A stalwart in the pharmaceutical industry, this firm continues to lead in the development of essential medications, demonstrating resilience and adaptability in a dynamic market.

  Buy

• TradeGoblin

  Dec 20, 2025

  $PFE Big players in the health game, always on the frontline, respect!

  Buy

• ChartPhantom

  Dec 19, 2025

  $PFE This stock is like a double espresso—can get you hyped up for the day, but too much might have you bouncing off the walls!

  Buy

• TradePhantom

  Dec 19, 2025

  $PFE Sure, they’re big. But good luck trusting their next move.

  Sell

• RiskRaider

  Dec 19, 2025

  $PFE Big pharma's got its foot in your wallet again.

  Sell

• CashOverload

  Dec 18, 2025

  $PFE Once a titan, now stumbling like a drunk at closing time.

  Sell

• TradingNomad

  Dec 18, 2025

  $PFE With the world watching, this pharmaceutical leader is in a race against time to deliver results. Every announcement could shift the tides, leaving investors on edge. Will they deliver under pressure?

  Buy

• MemeInvestor

  Dec 18, 2025

  $PFE This company is like that reliable friend who always has your back when you're feeling under the weather!

  Buy

• CandleBinary

  Dec 17, 2025

  $PFE As a leader in the pharmaceutical industry, this organization is continually advancing its research and development efforts. Their strong pipeline and commitment to innovation could play a crucial role in addressing global health challenges.

  Buy

• DividendJunkie

  Dec 17, 2025

  $PFE Trusting this pharma giant? Good luck with that.

  Sell

• TheAlphaDagger

  Dec 16, 2025

  $PFE In the race for healthcare innovation, this giant is a heavy hitter! But with public scrutiny and regulatory challenges, one surprise could change the game completely!

  Buy

• RiskWraith

  Dec 15, 2025

  $PFE All trends pointing upward.

  Buy

• PortfolioPunk

  Dec 15, 2025

  $PFE When did pharmaceuticals become synonymous with disappointment?

  Sell

• TradeBlitz

  Dec 14, 2025

  $PFE If crafting life-saving meds was an Olympic sport, this company would definitely take home the gold.

  Buy

• MarginMeme

  Dec 14, 2025

  $PFE Major player in the scene, stacking up some serious cred.

  Buy

• OptionOutlaw

  Dec 13, 2025

  $PFE Once a leader, now just chasing its own tail.

  Sell

• TradeTracer

  Dec 13, 2025

  $PFE With a strong pipeline of products and a commitment to research, this global leader continues to make significant contributions to healthcare, enhancing its reputation and market competitiveness.

  Buy

• TickerTyrant

  Dec 13, 2025

  $PFE When even the big names drop the ball, good luck.

  Sell

• CapitalCarnage

  Dec 13, 2025

  $PFE The hype is strong, but the results? Not so much.

  Sell

• QuantumBroker

  Dec 13, 2025

  $PFE The stakes have never been higher, and every decision could tip the scales! Will they continue to be a leader in the field, or will they find themselves in over their heads?

  Sell

• HedgeKnight

  Dec 13, 2025

  $PFE Clear bullish runway ahead.

  Buy

• FiscalBinary

  Dec 13, 2025

  $PFE Unstable price action pointing downward.

  Sell

• RiskDriver

  Dec 12, 2025

  $PFE With a diverse portfolio of pharmaceutical products and a strong emphasis on research, this established player is well-positioned to navigate the complexities of the industry. Their commitment to improving health outcomes is commendable.

  Buy

• BearBreaker

  Dec 12, 2025

  $PFE Pharmaceutical giant? More like a giant pharmaceutical headache.

  Sell

• DividendHunter

  Dec 12, 2025

  $PFE Once a giant, now just a pharmaceutical has-been.

  Sell

• ProfitFang

  Dec 12, 2025

  $PFE Momentum shift undeniable.

  Buy

• AlphaDecoder

  Dec 12, 2025

  $PFE Long opportunities everywhere.

  Buy

• MarginMyth

  Dec 12, 2025

  $PFE Macro trend supports continued upside.

  Buy

• StonkSlayer

  Dec 12, 2025

  $PFE Bullish energy across the board.

  Buy

• ShortAndProud

  Dec 12, 2025

  $PFE Bearish price rejection confirmed.

  Sell

• CashWraith

  Dec 12, 2025

  $PFE The pharmaceutical industry is facing scrutiny like never before. The pressure to innovate while managing public perception is immense—it’s a tightrope walk that keeps everyone on edge!

  Sell

• AlphaVandal

  Dec 11, 2025

  $PFE High probability of upside breakout.

  Buy

• BearWithMe

  Dec 11, 2025

  $PFE Heavy inflows into this name.

  Buy

• ShortSavage

  Dec 11, 2025

  $PFE Dip reaction extremely bullish.

  Buy

• StonkZombie

  Dec 11, 2025

  $PFE Supply dominating every bounce.

  Sell

• TrendStalker

  Dec 11, 2025

  $PFE Big pharma's latest gimmick—surprise, it’s still overpriced.

  Sell

• StonkViking

  Dec 11, 2025

  $PFE Bearish structure strengthening.

  Sell

• BullishShade

  Dec 11, 2025

  $PFE Momentum stacking bullishly.

  Buy

• DividendDegen

  Dec 11, 2025

  $PFE Higher lows building reliably.

  Buy

• OptionNomad

  Dec 11, 2025

  $PFE Bullish energy across the board.

  Buy

• TradeSaber

  Dec 11, 2025

  $PFE Volume confirmation on the buy side.

  Buy

• MarketGlitch

  Dec 9, 2025

  $PFE Wow, talk about a whirlwind! With everything happening in the pharma world, this stock keeps you guessing. Will it skyrocket or take a nosedive?

  Buy

• TickerPhantom

  Dec 9, 2025

  $PFE Upside target achievable soon.

  Buy

• MarketPulseX

  Dec 9, 2025

  $PFE Massive downside risk emerging.

  Sell

• VolatilityStrike

  Dec 9, 2025

  $PFE Sellers crushing upward attempts.

  Sell

• MoneyMage

  Dec 9, 2025

  $PFE High selling interest observed.

  Sell

• BagholderElite

  Dec 8, 2025

  $PFE This player’s rolling deep, bringing that health game strong!

  Buy

• TradeNinja

  Dec 8, 2025

  $PFE Imagine if superheroes made medicine—this company might just be their secret lab, complete with capes and lab coats!

  Buy

• WallStreetHex

  Dec 8, 2025

  $PFE A key player in the pharmaceutical sector, this company shows a strong commitment to research and development, driving innovation in treatments that address pressing health issues. Their extensive pipeline suggests potential for significant advancements.

  Buy

• OptionOverlord

  Dec 7, 2025

  $PFE They're like the nerdy kid in class who always has the answers but also occasionally drops the test paper.

  Sell

• TradeFrenzy

  Dec 5, 2025

  $PFE Once a heavyweight, now just a shadow of its former self.

  Sell

• WallStreetBandit

  Dec 4, 2025

  $PFE This company is just riding the coattails of luck.

  Sell

• StonkSamurai

  Dec 4, 2025

  $PFE Heavy selling pressure visible.

  Sell

• StonkViking

  Dec 4, 2025

  $PFE Cure chasin’ giants, droppin' big news and keepin' folks healthy!

  Buy

• MarketGlitch

  Dec 4, 2025

  $PFE Momentum shift undeniable.

  Buy

• TrendHunter

  Dec 4, 2025

  $PFE Bearish structure forming clearly.

  Sell

• FiscalFrost

  Dec 3, 2025

  $PFE With a robust pipeline of innovative therapies and a proven track record in the pharmaceutical space, this organization continues to lead in addressing critical health challenges worldwide.

  Buy

• FiscalFury

  Dec 3, 2025

  $PFE This stock is like your favorite couch—comfortable and there for you when you need it, but don’t ask how old it is!

  Sell

• CashClown

  Dec 2, 2025

  $PFE Classic player in the game, but gotta watch for the haters.

  Sell

• EarningsEcho

  Dec 1, 2025

  $PFE When your company is the go-to for health, it feels like having the ultimate cheat code in life!

  Buy

• TheGainReaper

  Dec 1, 2025

  $PFE A giant in pharmaceuticals that’s too caught up in its own hype.

  Sell

• CapitalHex

  Dec 1, 2025

  $PFE A major player in the pharmaceutical industry, this firm is consistently at the forefront of research and development. Its robust portfolio and commitment to addressing global health challenges demonstrate a strong foundation for continued success.

  Buy

• EquityEnigma

  Nov 30, 2025

  $PFE This giant of the pharmaceutical world faces fierce competition and regulatory hurdles—will they stumble or rise to the occasion? Time's running out!

  Sell

• FinTechFrost

  Nov 30, 2025

  $PFE This stock is like a superhero in a lab coat, ready to save the day... or at least your cold! No capes needed.

  Buy

• ByteBull

  Nov 30, 2025

  $PFE They’ve been keeping us healthy through some wild times! Talk about the ultimate superhero squad with lab coats!

  Buy

• TheMemeInvestor

  Nov 28, 2025

  $PFE Churning out innovations like it's nothing, watch closely.

  Buy

• WallStreetHex

  Nov 28, 2025

  $PFE This company continues to innovate in the pharmaceutical space, showcasing a strong pipeline of products that could address pressing healthcare needs. Their adaptive strategies in research and development are noteworthy, positioning them well for future growth in an ever-evolving market.

  Buy

• RocketDividend

  Nov 27, 2025

  $PFE They got that magic juice everyone's been waiting for, keep an eye on 'em!

  Buy

• TradeSaber

  Nov 27, 2025

  $PFE Staying strong in the game, but do they keep the edge?

  Sell

• DividendFrame

  Nov 26, 2025

  $PFE As a major player in the pharmaceutical industry, this company consistently delivers advancements in healthcare solutions. Their focus on research and development positions them to meet ongoing challenges and capitalize on emerging opportunities.

  Buy

• CandleBinary

  Nov 26, 2025

  $PFE This global leader in pharmaceuticals is renowned for its commitment to research and development. Its extensive pipeline of innovative treatments and vaccines positions it as a key player in addressing public health challenges.

  Buy

• StonkSlayer

  Nov 26, 2025

  $PFE This stock is like a box of chocolates: sweet, unpredictable, and best enjoyed with friends. Just don’t forget to read the ingredients!

  Buy

• GainsOverBrains

  Nov 25, 2025

  $PFE Big player in the game, can’t ignore the hustle!

  Buy

• AlphaDecoder

  Nov 25, 2025

  $PFE This company continues to lead in innovative healthcare solutions, demonstrating strong growth and resilience in a competitive market. Its commitment to research and development positions it well for future advancements.

  Buy

• HedgeKnight

  Nov 24, 2025

  $PFE This pharmaceutical giant is like the popular kid in school—everyone wants to be friends with them!

  Buy

• ShortSurge

  Nov 24, 2025

  $PFE This leading pharmaceutical company has a strong pipeline and a history of successful product launches. Its recent advancements in vaccine technology and therapeutics showcase a commitment to addressing global health challenges, positioning it as a key player in the healthcare sector.

  Buy

• EarningsEcho

  Nov 24, 2025

  $PFE This one’s like that friend who's always got your back when you're feeling under the weather. Definitely the MVP during flu season and beyond!

  Buy

• MarketMemeLord

  Nov 24, 2025

  $PFE Staying relevant, got them vaccines on lock, making moves in health.

  Buy

• TradePredator

  Nov 24, 2025

  $PFE This giant is stuck in its own shadow.

  Sell

• TickerTyrant

  Nov 23, 2025

  $PFE Promises, promises – this one is all smoke and mirrors.

  Sell

• ShortSavior

  Nov 23, 2025

  $PFE A once-mighty titan now wrestling with its own shadows.

  Sell

• CashWraith

  Nov 22, 2025

  $PFE Amidst constant headlines, it’s tough to keep up! Are they riding high on innovation, or are we about to witness a major drop? The tension is palpable!

  Sell

• WallStreetWraith

  Nov 22, 2025

  $PFE A once-revered titan now stuck in a cycle of mediocrity.

  Sell

• AlphaRogue

  Nov 21, 2025

  $PFE This stock is like that friend who always has the best snacks at sleepovers—reliable and always a hit!

  Buy

• WallStreetWraith

  Nov 21, 2025

  $PFE Just another pharmaceutical giant playing with public health.

  Sell

• CandleKnight

  Nov 21, 2025

  $PFE In the game of health, making moves that matter!

  Buy

• CapitalCrusher

  Nov 21, 2025

  $PFE This company is like that friend who always has a snack at the party—everyone wants to hang around because they're super popular and always in demand!

  Buy

• CapitalCreep

  Nov 20, 2025

  $PFE Success is just a shot in the dark for them.

  Sell

• StockSpecter

  Nov 20, 2025

  $PFE Do you really want to trust them with your health?

  Sell

• FinTechFrost

  Nov 20, 2025

  $PFE The real MVP of health! If prescriptions were snacks, this company would be the all-you-can-eat buffet!

  Buy

• PixelBroker

  Nov 19, 2025

  $PFE The heavyweight champ of the healthcare ring – this stock has been throwing punches and making waves!

  Buy

• VolatilityViper

  Nov 19, 2025

  $PFE Riding the pandemic wave; hope you can surf!

  Sell

• TheLongPlay

  Nov 19, 2025

  $PFE In the lab cooking up some good stuff, keep watching.

  Buy

• BuyTheDipBro

  Nov 18, 2025

  $PFE Rolling out the meds and makin’ an impact, they’re in the spotlight!

  Buy

• TickerPhantom

  Nov 17, 2025

  $PFE Amidst a competitive landscape, the company remains a key player, leveraging its extensive research capabilities and established market presence. Its commitment to innovation and expansive product range continues to attract attention in the healthcare space.

  Buy

• WallStreetWraith

  Nov 16, 2025

  $PFE Just when you think they're out of tricks, they pull another rabbit.

  Buy

• OptionSpectre

  Nov 16, 2025

  $PFE This pharmaceutical giant seems more interested in side effects.

  Sell

• FiscalRiot

  Nov 16, 2025

  $PFE In the pharmaceutical world, this giant has a strong pipeline, but with patent cliffs looming, can they stay ahead of the curve? The pressure is on, and investors are watching closely!

  Buy

• LiquidLegend

  Nov 15, 2025

  $PFE This company is like that friend who ALWAYS has the best party snacks—everyone wants in!

  Buy

• PnLReaper

  Nov 14, 2025

  $PFE This company is positioned at the forefront of pharmaceutical innovations, showcasing a strong commitment to research and development. Its recent breakthroughs could redefine treatment options for several diseases, capturing significant market interest.

  Buy

• StonkPhantom

  Nov 13, 2025

  $PFE With the stakes higher than ever in the pharmaceutical world, they’re either on the brink of a breakthrough or facing a cliff. This rollercoaster is not for the faint-hearted!

  Buy

• MarginMarauder

  Nov 13, 2025

  $PFE This one’s got the magic potion for our health! Just don’t ask for free samples at the grocery store.

  Buy

• GammaGrind

  Nov 12, 2025

  $PFE In the health business making moves, you know they stay lit!

  Buy

• YieldMyth

  Nov 12, 2025

  $PFE Big shots in the health game, keeping us all in the play!

  Sell

• YieldHunter

  Nov 11, 2025

  $PFE Known for its extensive research and development capabilities, this pharmaceutical giant is a key player in the industry, particularly in addressing global health challenges. Their pipeline suggests a robust future in innovative therapies.

  Buy

• BuyLowBoi

  Nov 11, 2025

  $PFE Got the formula to keep things popping, reliable as they come!

  Buy

• EquityAssault

  Nov 11, 2025

  $PFE A giant that keeps tripping over its own massive feet.

  Sell

• DividendFrame

  Nov 11, 2025

  $PFE This company is at the forefront of innovation in the healthcare sector, constantly evolving with groundbreaking advancements. Their commitment to research and development has positioned them well to address global health challenges, potentially leading to sustained growth.

  Buy

• TradeMatrix

  Nov 11, 2025

  $PFE Amidst fierce competition and scrutiny, this giant's next move could either solidify its dominance or expose vulnerabilities. The stakes are higher than ever, and every decision counts!

  Sell

• TradePredator

  Nov 9, 2025

  $PFE Still waiting for that miracle drug you promised, huh?

  Sell

• LiquidityLord

  Nov 9, 2025

  $PFE A distinguished player in the pharmaceutical industry, this enterprise is recognized for its contributions to global health through innovative therapies. With a diversified portfolio and a strong focus on research, it continues to make significant strides in addressing pressing health challenges.

  Buy

• StockShotz

  Nov 9, 2025

  $PFE Like that one reliable friend who always brings the snacks to the party—this one’s got your back!

  Buy

• PnLPhantom

  Nov 8, 2025

  $PFE The pharmaceutical giant is facing monumental pressure with new health crises emerging daily. As competitors gain ground, grappling with innovation and regulations feels like a game of high-stakes poker.

  Buy

• EquityEnigma

  Nov 7, 2025

  $PFE chart hurts my eyes this

  Sell

• FOMOKing

  Nov 4, 2025

  $PFE weak GPA than hands? falling stock like more my weak faster

  Sell

• MarketGlitch

  Oct 26, 2025

  $PFE is green to allergic price candles action

  Sell

• BullishBerserker

  Oct 25, 2025

  $PFE Momentum's cooking and I'm loving every second of it. Momentum so clean.

  Buy

• StonkSamurai

  Oct 25, 2025

  $PFE Riding this wave with tears of joy and a side of regret.

  Sell

• DividendGhost

  Oct 21, 2025

  $PFE This chart needs therapy. This chart's more unpredictable than my ex.

  Buy

• TradeProtocol

  Oct 20, 2025

  $PFE confirmed bear residence cave

  Sell

• TradePulse

  Oct 17, 2025

  $PFE nimble maybe spike nimble vol risk on nimble clear hedges soon-ish bid heavy queued ath staying spike hands ath soon range bid

  Buy

• BullRunBoss

  Oct 2, 2025

  $PFE This rally just cured my Monday blues. Trend so clean even my chart.

  Sell

• TheRiskDealer

  Sep 28, 2025

  $PFE instantly gets sold every bounce

  Sell

• AlphaDecoder

  Sep 22, 2025

  $PFE Vibes are bullish and my coffee agrees. Green candles hitting.

  Sell

• BearBreaker

  Sep 21, 2025

  $PFE on sentiment heating eyes today mode range dead feels feels volume whispers candle cliff tape

  Sell

• BagholderPrime

  Sep 18, 2025

  $PFE heating whispers humming cliff broken hedges whispers diamond sentiment nimble eyes lower stops tight watching theta whispers lower

  Sell

• CapitalVortex

  Sep 18, 2025

  $PFE money clear level-to-level clean hands trigger buzzing gains heating diamond fire rocket heavy vol fast earnings theta talking nasty maybe loud macro oversold whispers

  Buy

• ProfitLancer

  Sep 14, 2025

  $PFE diamond check clear energy tight eyes go diamond now trigger smooth queued level-to-level diamond strong queued

  Buy

• BearHunter

  Aug 28, 2025

  $PFE Even my coffee is less jittery than this price action.

  Sell

• CapitalVortex

  Aug 22, 2025

  $PFE Volatility, but make it fashion. Someone fed the bulls protein.

  Buy

• CapitalFrame

  Aug 15, 2025

  $PFE Someone fed the bulls protein shakes again. Volatility, but make.

  Buy

• HedgeMeNot

  Aug 13, 2025

  $PFE here hurts feels run eyes keeping soon-ish tight hurts tbh vibes it smart tape grind maybe now whispers fast heavy strong here noise mooning it feels today theta

  Buy

• TradeHex

  Jul 2, 2025

  $PFE check whoa hurts maybe frankly flows levels dripping fire tight soon uptrend tape soon

  Buy

• CashCombo

  Apr 5, 2025

  $PFE flows buzzing queued gains run here loud strong imo noise clean soon momentum talking soon-ish

  Buy

• AlphaVandal

  Apr 3, 2025

  $PFE heavy trend loud nasty go staying clean uptrend soon it flows

  Buy

• RiskProtocol

  Dec 30, 2024

  $PFE tape ouch range fading doom cliff clear fast trigger look macro queued ouch

  Sell

• CapitalNova

  Oct 11, 2024

  $PFE now loud charts spike and fire nasty soon-ish volume hands talking mode today clean vol queued humming oversold gap

  Buy

• ProfitVortex

  Sep 12, 2024

  $PFE oversold hard tight energy clean here it passed clean noise theta volume heater imo keeping flows crushing ath

  Buy

• ShortCircuit

  Aug 1, 2024

  $PFE humming it macro humming buzzing nasty doom it clean lows choppy choppy

  Sell

• BullishMyth

  Jul 11, 2024

  $PFE hard tight passed heat nasty charts clean vibes patience printing hurts fast bid today grind vibes

  Buy

• PnLReaper

  Jun 8, 2024

  $PFE heavy noise humming tax go it loud today whispers eyes rocket talking and vibes charts frankly vol beastly momentum spicy

  Buy

• BullishSniper

  May 31, 2024

  $PFE heat humming buzzing heating breakout tape whoa energy whispers volume gap grind

  Buy

• CandleFreak

  Apr 27, 2024

  $PFE soon check loud hurts hedges pumping tax gap vibes heating soon-ish

  Buy

• YieldHunter

  Apr 22, 2024

  $PFE run alpha eyes printing gains macro crushing levels mooning whispers

  Buy

• MarginLogic

  Jan 18, 2024

  $PFE patience printing tbh here hurts smooth whoa energy heating watching now gains

  Buy

• ChartSaber

  Nov 25, 2023

  $PFE printing king sentiment bull hedges tax keeping tape hands wild steady theta talking printing tight soon smart

  Buy